Stock Overview

Agilent Technologies Inc (A)

NYSE · Healthcare · Diagnostics & Research

Agilent Technologies Inc is a Healthcare company with a market capitalization of $38.41B, a trailing P/E ratio of 27.3, and a dividend yield of 0.74%.

Market Cap
$38.41B
P/E (TTM)
27.3
Forward P/E
22.4
Price/Sales
5.3
Price/Book
5.4
EV/EBITDA
20.3
Dividend Yield
0.74%
Beta
1.26
EPS (TTM)
$4.99
Profit Margin
19.6%
ROE
21.3%
52W High
$159.62
52W Low
$108.35

5-Year Price History

Latest Annual Financials · FY ending October 31, 2025

Revenue
$6.95B
Gross Profit
$3.64B
Operating Income
$1.48B
Net Income
$1.30B
Free Cash Flow
$1.15B
Total Debt
$3.35B
Cash & Equivalents
$1.79B
Shareholder Equity
$6.74B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q2 2026May 27, 2026$1.49$1.41+5.7%
Q1 2026February 25, 2026$1.07$1.24-13.7%
Q4 2025November 24, 2025$1.59$1.58+0.6%
Q3 2025August 27, 2025$1.37$1.37+0.0%
Q2 2025May 28, 2025$1.31$1.26+4.0%
Q1 2025February 26, 2025$1.31$1.27+3.1%

Other Diagnostics & Research Stocks

Frequently Asked Questions

What is Agilent Technologies Inc's market cap?

As of June 29, 2026, Agilent Technologies Inc (A) has a market capitalization of $38.41B.

What is Agilent Technologies Inc's P/E ratio?

Agilent Technologies Inc trades at a trailing price-to-earnings (P/E) ratio of 27.3. Its forward P/E is 22.4.

Does Agilent Technologies Inc pay a dividend?

Yes — Agilent Technologies Inc pays a dividend yielding 0.74%, an annual payout of $1.01 per share.

What sector is A in?

Agilent Technologies Inc is in the Healthcare sector, specifically the Diagnostics & Research industry.

What was Agilent Technologies Inc's revenue?

In its latest reported fiscal year (ending October 31, 2025), Agilent Technologies Inc reported revenue of $6.95B and net income of $1.30B.

Ask your own questions about A

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.